Originator branded anti-bacterial drugs with high manufacturing quality standards have captured significant growth momentum and maintained double digits growth in recent years in China. 


We have two flagship originator branded anti-bacterial drugs,Vancocin® and Ceclor®. Vancocin® is the originator branded product of  of vancomycin.It is the only first-line drug for the treatment of MRSA infections in the NRDL.  Ceclor® is a market leading anti-bacterial drug for pediatric use in China. 


Our Ceclor manufacturing facility located in Suzhou is equiped with state-of-the-art equipment,modules and production lines, achieving high quality consistency and lean operations,which produce reliable Ceclor products for patients in China.


Originator branded anti-bacterial drugs with high manufacturing quality standards have captured significant growth momentum and maintained double digits growth in recent years in China. 


We have two flagship originator branded anti-bacterial drugs,Vancocin® and Ceclor®. Vancocin® is the originator branded product of  of vancomycin.It is the only first-line drug for the treatment of MRSA infections in the NRDL.  Ceclor® is a market leading anti-bacterial drug for pediatric use in China. 


Our Ceclor manufacturing facility located in Suzhou is equiped with state-of-the-art equipment,modules and production lines, achieving high quality consistency and lean operations,which produce reliable Ceclor products for patients in China.


Cerebrovascular disease (CVD) is one of the most prevalent diseases in China. CV deaths, strokes and heart attacks represent the leading causes of death and disability in China. Statin therapy is the current mainstay for CV risk reduction, which may reduce the risk of major CV events by approximately 25% to 35%, leaving significant persistent CV risk of approximately 65% to 75%. 


Icosapent Ethyl (the generic name of Vascepa) is a transformative drug candidate for reducing CV events and is the first and only drug approved by the FDA as an adjunct to maximally tolerated statin therapy for reducing persistent CV risk in certain high-risk patients. We in-licensed Vascepa® from Amarin in February 2015 for development and commercialization.



Cerebrovascular disease (CVD) is one of the most prevalent diseases in China. CV deaths, strokes and heart attacks represent the leading causes of death and disability in China. Statin therapy is the current mainstay for CV risk reduction, which may reduce the risk of major CV events by approximately 25% to 35%, leaving significant persistent CV risk of approximately 65% to 75%. 


Icosapent Ethyl (the generic name of Vascepa) is a transformative drug candidate for reducing CV events and is the first and only drug approved by the FDA as an adjunct to maximally tolerated statin therapy for reducing persistent CV risk in certain high-risk patients. We in-licensed Vascepa® from Amarin in February 2015 for development and commercialization.



Respiratory system is one of the fastest-growing and emerging therapeutic areas in China. Both asthma and COPD have strong prevalence in China and have been significantly underdiagnosed and undertreated.The Health China 2030 plan set a target to significantly increase diagnosis rate of COPD and lower the mortality rate of COPD.


ICSs are by far the most effective controller used in the treatment of asthma and COPD and the only type of drugs that can effectively suppress the characteristic inflammation in asthmatic airways. FPN is the latest-generation ICS nebulizer indicated for the treatment of asthma. Also, we are developing generic versions of two ICS/LABA combination DPI drug, ERC 301 and ERC 302 for treatment of asthma and COPD.


ERC, our respiratory R&D Center, with the robust and proprietary quality management system, is dedicated to ensuring high quality standards of the respiratory products in the future.

Respiratory system is one of the fastest-growing and emerging therapeutic areas in China. Both asthma and COPD have strong prevalence in China and have been significantly underdiagnosed and undertreated.The Health China 2030 plan set a target to significantly increase diagnosis rate of COPD and lower the mortality rate of COPD.


ICSs are by far the most effective controller used in the treatment of asthma and COPD and the only type of drugs that can effectively suppress the characteristic inflammation in asthmatic airways. FPN is the latest-generation ICS nebulizer indicated for the treatment of asthma. Also, we are developing generic versions of two ICS/LABA combination DPI drug, ERC 301 and ERC 302 for treatment of asthma and COPD.


ERC, our respiratory R&D Center, with the robust and proprietary quality management system, is dedicated to ensuring high quality standards of the respiratory products in the future.

There are other branded drugs operating on our platform, covering the area of hematology, nervous system diseases, medical nutrition and many other fields,creating a diversified product portfolio to provide more options for Chinese patients.

There are other branded drugs operating on our platform, covering the area of hematology, nervous system diseases, medical nutrition and many other fields,creating a diversified product portfolio to provide more options for Chinese patients.

Unit 122-129, Building A3 No.700, Wanrong Road,Shanghai

publication@eddingpharm.com

沪ICP备2021007464号

Copyright © 2019 亿腾医药 版权所有

药监局备案号: (沪) -非经营性-2021-0038